Zantac 75 Relief tablets

Country: United Kingdom

Language: English

Source: MHRA (Medicines & Healthcare Products Regulatory Agency)

Active ingredient:

Ranitidine hydrochloride

Available from:

Omega Pharma Ltd

ATC code:

A02BA02

INN (International Name):

Ranitidine hydrochloride

Dosage:

75mg

Pharmaceutical form:

Oral tablet

Administration route:

Oral

Class:

No Controlled Drug Status

Prescription type:

Valid as a prescribable product

Product summary:

BNF: 01030100; GTIN: 5000347079122 5000347079160

Patient Information leaflet

70
11
9
11
11
9
11
70
9
MANUFACTURED BY: Glaxo Wellcome SA, Aranda de Duero,
Burgos, Spain or Omega Pharma International,
Venecoweg 26, B-9810 Nazareth, Belgium.
or Famar Italia S.p.A, Via Zambeletti, 25
20021 - Baranzate (MI) ITALY
This leaflet was revised in March 2016.
REPORTING OF SIDE EFFECTS: If you get any side effects, talk
to your doctor, pharmacist or nurse. This includes any
possible side effects not listed in this leaflet. You can also
report side effects directly via the Yellow Card Scheme at:
www.mhra.gov.uk/yellowcard
By reporting side effects, you can help provide more
information on the safety of this medicine.
Store below 25˚C. Tablets should not be removed from
blisters until immediately prior to use.
Keep out of the reach and sight of children.
DO NOT USE THIS MEDICINE AFTER THE ‘EXP’ DATE SHOWN ON
THE PACK.
Talk to your doctor or pharmacist before taking Zantac
75 Relief if you are taking any other medicines, including
those obtained without a prescription; particularly
MEDICINES TO PREVENT BLOOD CLOTTING, such as WARFARIN,
medicines for insomnia (e.g. triazolam, midazolam),
medicines for lowering blood glucose (e.g. glipizide),
medicines for fungal infections (e.g. ketoconazole,
itraconazole, posaconazole), medicines for treating HIV
infection (e.g. atazanavir, delavirdine), medicines for lung
cancer (e.g. gefitnib) and NON-STEROIDAL
ANTI-INFLAMMATORY PAINKILLERS (e.g. ASPIRIN or IBUPROFEN).
This advice is even more important if you are elderly.
LF03526E 2623602 / IS-150-152-60B2
25
File title:
9773_LF03526E_2623602_ZANTAC RELIEF 75 6S-12S LEAFLET_UK V6
Item No.:
2623602
OPI No.:
LF03526E
Replacement No.:
...
Last edit:
28th April 2016
Brand:
ZANTAC
Variant:
Relief 75 mg tablets
Component:
Leaflet
Market/s:
UK
Dimensions:
152 x 150 mm CG283_IS-150-152-60B2
Reel Unwind:
...
Spec. Ref.:
...
Substrate:
White Paper
PharmaCode:
25
EAN Code:
N/A
Other Code/Spec.:
...
Manufacturing Site:
FAMAR IT
Printer:
...
No. of Colours:
1
Process Black
Cutter

Summary of Product characteristics

OBJECT 1
ZANTAC 75 RELIEF
Summary of Product Characteristics Updated 08-Jul-2016 | Omega Pharma
Ltd
1. Name of the medicinal product
Zantac 75 Relief
2. Qualitative and quantitative composition
Quantities per tablet
Active Ingredient:
Ranitidine Hydrochloride 84mg
(equivalent to ranitidine 75mg)
3. Pharmaceutical form
Tablet
4. Clinical particulars
4.1 Therapeutic indications
Symptomatic relief of heartburn, indigestion, acid indigestion and
hyperacidity.
4.2 Posology and method of administration
Route of Administration
Oral
Dosage
Adults (Including the elderly) and children 16 years of age and older:
Swallow one Zantac 75 Relief tablet whole, with a drink of water, as
soon as you have symptoms. If
symptoms persist for more than one hour or return, take another
tablet. Do not take more than two tablets
in 24 hours.
Do not take the tablets for more than 6 days without the advice of a
pharmacist or doctor.
Children under 16 years
Not recommended for children under 16 years of age.
4.3 Contraindications
Ranitidine is contraindicated for people known to be hypersensitive to
the drug or any of the ingredients
of Zantac 75 Relief tablets.
4.4 Special warnings and precautions for use
Treatment with a histamine H
2
-antagonist such as Zantac 75 Relief may mask symptoms associated with
carcinoma of the stomach and may therefore delay diagnosis of the
condition.
Ranitidine is excreted via the kidney and so plasma levels of the drug
are increased in patients with renal
impairment (creatinine clearance less than 50 ml/min). Zantac 75
Relief is not suitable for these patients
without medical supervision.
People taking non-steroidal anti-inflammatory drugs, especially those
with a history of peptic ulcer and
the elderly, should not self-medicate with Zantac 75 Relief but seek
their doctor's advice before use.
People with a history of porphyria should avoid use of the product.
Consumers will be advised not to purchase a second pack of tablets
without the advice of a pharmacist of
doctor.
The product is not indicated in the foll